- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03587038
OKN-007, 신규 교모세포종 진단에 테모졸로마이드 보조 화학방사선요법과 병용
새로 진단된 교모세포종 환자에서 보조 테모졸로마이드 화학방사선 요법과 OKN-007의 타당성 파일럿 연구
This is a pilot study exploring the potential benefit of adding OKN-007 with Temozolomide for treatment in patients with malignant Glioblastoma undergoing adjuvant concomitant radiotherapy. This drug combination is expected to have an anti-cancer effect in patients who have experienced disease progression after first line treatment.
연구 개요
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73117
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients have newly diagnosed histologically proven WHO grade III or grade IV Glioblastoma Multiforme (GBM).
- Patients at initial presentation of GBM must undergo an adequate surgical resection of the primary lesion; patients must be registered within 49 days (7 weeks) of the surgery.
- Patients must have available and be willing to submit a minimum of five unstained slides tumor tissue specimens from the GBM surgery or open biopsy for MGMT status analysis and molecular profile analysis.
- ECOG performance status within 0 - 2
- Full recovery (< grade 1) from the adverse events associated with prior surgery or any earlier intervention and a minimum of 28 days from the administration of any investigational agent
- Adequate renal, liver and bone marrow function: Leukocytes >3,000/mcL; Absolute neutrophil count >1,500/mcL; Platelets >100,000/mcL; AST / ALT (SGPT) <2.5 x ULN; Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) (except Gilbert's Syndrome, who must have a total bilirubin < 3.0 mg/dL); Creatinine within normal limits
- Patients must be ≥ 18 years of age
- Patients must be willing to have blood draws for PK analysis
- All patients must have a CT or MRI of the brain within 14 days prior to registration. The brain CT or MRI should be performed with intravenous contrast (unless contraindicated).
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines.
- Life expectancy ≥ 3 months, allowing adequate follow up of toxicity evaluation and progression-free survival evaluation;
- Female patient, if of childbearing potential, has a negative serum pregnancy test within 72 hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment
- Male patient agrees to use an adequate method of contraception
- Birth control should be used from the signing of the patient consent form and for 120 days following the last dose of study treatment.
- In addition, men must not donate sperm during study therapy and for 120 days after receiving the last dose of study treatment.
Exclusion Criteria:
- Second primary malignancy (except adequately treated basal cell carcinoma of the skin).
- Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible
- Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry
- Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study
- Patients with moderate or severe renal impairment (calculated creatinine clearance of < 60 mL/min)
- Patients with sodium, potassium, or creatinine serum electrolytes > grade 2.
- Screening ECG abnormality documented by the investigator as medically significant
- Inability to comply with protocol or study procedures.
- Women who are pregnant or breastfeeding.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: OKN-007 3 days per week plus temozolomide
OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions |
400 mg OKN-007/mL in a phosphate buffer 75 mg/m2 standard of care treatment to be given 1 to 2 hours after OKN-007 |
|
실험적: OKN-007 5 days per week and temozolomide
OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions |
400 mg OKN-007/mL in a phosphate buffer 75 mg/m2 standard of care treatment to be given 1 to 2 hours after OKN-007 |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The maximum tolerated dose and the type of dose limiting toxicities
기간: 5 years
|
To determine how well patients are able to tolerate combination of OKN-007, temozolomide, and radiotherapy. Adverse events will be tabulated using MedDRA. The severity of the AE will be graded by the Investigator using the NCI CTCAE, version 4.03. |
5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants who experience progression-free survival
기간: 5 years
|
To evaluate the proportion of patients who receive combination OKN-007 and TMZ who do not experience progression |
5 years
|
|
Number of participants who comply with study treatment plan
기간: 5 years
|
To evaluate the clinical compliance of participants receiving combination OKN-007 and TMZ |
5 years
|
|
Number of participants who are able to receive a reduction in steroid dose
기간: 5 years
|
To evaluate whether study drug combination allows for a reduced steroid dosage |
5 years
|
|
Number of participants who experience overall survival
기간: 5 years
|
To evaluate the proportion of patients who receive combination OKN-007 and TMZ who experience overall survival |
5 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: James Battiste, MD, Principal Investigator
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- OU-SCC-Oblato-001
- OKN-007 (기타 보조금/기금 번호: Oblato Inc)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .